| Hosting Organization |
 |
 |
| Operating Organization |
Foreign Experts Databank
of SAFEA-Dalian Biotechnological and Medical Experts Subdivision
BIT Lifesciences, Inc. |
| Supporting Organization |
 |
| International Marketing Partner |
 |
|
Participants List
(Academia) |
National Yang-Ming University, Taiwan
Abyad Medical Center and Middle-East Longevity Institute, Lebanon
Akershus University Hospital, Norway
Aligarh M University, India
American University of Beirut, USA
Antwerp University Hospital, Belgium
Applied Proteomics and Molecular Medicine, USA
Aristotelian University of Thessaloniki, Greece
Banaras Hindu University, India
Barrow Neurological Institute, USA
Baylor College of Medicine, USA
Ben-Gurion University of the Negev, Israel
Boston University School of Medicine, USA
Cancer Research Technology, UK
CHDI Foundation, California
Chinese Academy of Sciences, China
CRG-Centre de Regulaci Genmica, Spain
CSIRO Molecular and Health Technologies, Australia
Duke University, USA
Emory University, USA
exas Southern University, USA
Florida A&M University, USA
Global Pathology Support, The Netherlands
Gujarat AIDS Awareness and Prevention Unit, India
Haematopoietic Stem Cell Laboratory, UK
Harvard Medical School, USA
Hospital S Hospital S Joao, Portugal
Human BioMolecular Re-. search Institute, USA
Indiana University School of Medicine, USA
Indiana University School of Medicine, USA
Innsbruck Medical University, Austria
Institute of Experimental Pharmacology, Slovak
Instituto De Biologia Experimentale Tecnologica, Portugal
Karolinska Institutet, Sweden
Keystone College Academia, USA
McGill University, Canada
Mercer University, USA
National Center for Toxicological Research, USA
National Institutes of Health, USA
Netherlands Cancer Institute, The Netherlands
New York Medical College, USA
Osaka University, Japan
Paul-Ehrlich-Institute, Germany
Penn State College of Medicine, USA
Pennsylvania State University College of Medicine, USA
Pharmacology Temple University, USA
Scientific Advisory Board Tolerx, USA
Shanghai Unviversity of Traditional Chinese Medicine, China
Solid Tumor Working Party, Italy
Stanford University, USA
Structural Genomics Consortium Karolinska Institutet, Sweden
Tabriz University of Medical Sciences, Iran
Technion - Israel Institute of Technology Rappaport Institute, Israel
The Babraham Institute, UK
The Hebrew University, Israel
The Institute of Cancer Research, UK
The University of Queensland, Australia
The University of Sydney, Australia
The University of Texas, USA
UC College of Medicine, USA
Universidade Federal Fluminense, Brazil
University Clinic Bonn, Germany
University of Basel, Switzerland
University of British Columbia, Canada
University of California, USA
University of California-San Francisco, USA
University of Camerino, Italy
University of Cape Town, USA
University of Colorado Health Sciences Center, USA
University of Crete, Greece
University of Geneva, Switzerland
University of Heidelberg, Germany
University of Hong Kong, China
University of Maryland School of Pharmacy, USA
University of Maryland, USA
University of Massachusetts Medical School, USA
University of Miami School of Medicine, USA
University of Miami, USA
University of Miami, USA
University of Oklahoma Health Sciences Center, USA
University of Siena, Italy
University of Southern Denmark, Denmark
University of Texas at Dallas, USA
University of Texas Health Science Center, USA
University of Texas Medical, USA
University of the Sciences in Philadelphia, USA
University of Utah School of Medicine, USA
University of Western Australia, Australia
Utah State University, USA
Virginia Commonwealth University, USA
University of Gothenburg, Sweden
|
Participants List
(Business) |
3 P Biopharmaceuticals, USA
Abbott Laboratories, USA
Adolor Corporation, USA
Affimed Therapeutics AG, Germany
AILERON Therapeutics, USA
Algorithme Pharma Inc., Canada
Allon Therapeutics Inc., USA
Alpha Cancer Technologies Inc., USA
Alpha-2 Pharmaceutica AB, Israel
Amgen, Inc., USA
Arena Pharmaceuticals, USA
Astellas Pharma Inc, Japan
Astellas Pharmaceutical Inc., Japan
AstraZeneca Pharmaceuticals, USA
AstraZeneca R&D Molndal, Sweden
Astrazeneca R&D Sodertolje, Sweden
AstraZeneca, UK
AstraZeneca, USA
AuxoCell Laboratories, Inc., USA
Avexa Ltd, Australia
Bayer HealthCare, USA
Bayer Schering Pharma AG, Germany
BellBrook Labs, LLC, USA
Biological Mimetics, Inc., USA
BioPerspectives, USA
Biota Holdings Limited, USA
Boehringer Ingelheim Pharmaceuticals, Inc., USA
Bristol-Myers Squibbs, USA
Centocor/Johnson & Johnson, USA
Chemistry Forma Therapeutics, Inc., Singapore
Coley Pharmaceutical GmbH, Germany
Cordex Pharma, Inc., USA
Cornerstone Pharmaceuticals, USA
Covidien, USA
Daiichi Sankyo Pharma Development, Japan
deCODE Chemistry, USA
DxS Ltd, USA
Eisai Co., Ltd., Japan
Elan Pharmaceuticals, USA
Europe GlaxoSmithKline R&D, UK
Genentech, USA
Genetix Ltd, UK
genscript, USA
Genzyme Pharmaceuticals, USA
Gilead Sciences Benzothiadiazine Hepatitis C NS5B, USA
Hoffmann-La Roche, Switzerland
ICON PLC, USA
IDDC Corporation, USA
Idera Pharmaceuticals, USA
Jesus College, England
Johnson & Johnson Pharmaceutical, USA
Johnson & Johnson Research Pty Limited, Australia
Laboratory Cellular Technology Ltd., USA
Lundbeck Research, USA
Mallinckrodt, Inc., USA
MDS Pharma Services, USA
Medimmune, UK
Merck & Co. Inc, USA
Merck & Co., Italy
Merck and Co., Inc., China
Merck KGaA, Germany
Merck Research Laboratories, USA
Nerviano Medical Sciences, Italy
Novartis Institutes for Biomedical Research, USA
Novartis Institutes, Switzerland
Novartis Pharmaceuticals Corporation, USA
Novartis, China
Ocimum Biosolutions, India
Ondokuz Mayis University, Turkey
OphthalmoPharma, Switzerland
Pfizer, USA
Pharmanet Development Group, Inc., USA
PharmaNet, Inc., USA
Ranbaxy Laboratories Limited, India
Reaction Biology Corporation, USA
RegPak BioPharma Consulting, The Netherlands
Sanofi Aventis, USA
Schering Plough Research Institute, USA
Schlich & Co, UK
Scott & White, USA
Sequoia Pharmaceuticals Inc., USA
SeraCare Life Sciences, USA
Shanghai Biochip Co., Ltd, China
Shenogen Pharma Group, China
Siena Biotech S.p.A. A company, USA
Simulations Plus, Inc., USA
Synta Pharmaceuticals Corp, USA
TEVA Pharmaceuticals, USA
The Takeda Oncology Company, USA
ThromboGenics, USA
Transgene, France
US Oncology Research, Inc., USA
Vaxinnate, USA
Wyeth Research, USA
XOMA (US) LLC, USA
Zeptosens C a Division of Bayer (Schweiz) AG, Switzerland
Zhejiang Hisun Pharmaceutical Co., Ltd, China
Tehran University of Medical Sciences , Iran
|
|
 |
|
 |
WCG 2009
(December 1-7, 2009, Foshan, China) |
 |
ICC 2009
(Dec. 5-7, 2009, Shanghai, China) |
 |
ICA 2010
(March 24-26, 2010, Beijing, China) |
 |
WCV 2010
(March 24-26, 2010, Beijing, China) |
 |
SEB 2010
(Apr. 22-24, 2010, Shanghai, China) |
|
|
|
| Submission Guidelines |
|
1. The organizers of IDDST Congress invite abstracts within the scope of the meeting. Submitted abstracts will be reviewed by experts and be scheduled for oral or poster presentation during the congress if the topic is relevant and the quality of the data justifies its scheduling. Irrelevant or poor-quality abstracts may be rejected.
2. Abstracts can only be submitted online via the congress website. It is advisable to prepare the complete abstract text and any figures/tables before accessing online abstract submission.
3. Abstracts need to written in clear English, taking into account the specifications below (see also sample on the next page):
a. Maximum word count abstract title: 20 words.
b. Maximum word count abstract text: 350 words (adjust in case of tables./figures).
c. Abstract topic should be selected during the online submission process from the list of predefined topics to facilitate abstract review and scheduling.
d. A minimum of three specific keywords should be added during online submission for indexing of the abstract. Specific keywords are: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied, biochemical or biological function(s) studied. Avoid the use of non-specific keywords, such as: angiogenesis, cell death, cancer, tumor, drug development, drug therapy. The World Cancer Congress reserves the rights to delete, edit, or add keywords to achieve uniformity throughout abstract publications.
e. Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract. Proprietary names may be used in the abstract text, not the abstract title, the first time the drug is mentioned there (put proprietary names between brackets).
f. The identity of a new, previously unpublished drug substance needs to be disclosed in the abstract, either by providing its structural formula or its full chemical name.
4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However, non-adherence to the above guidelines may be corrected (e.g. use of drug names, keywords) by the meeting organizers.
5. After submission, abstracts cannot be changed by the authors anymore. Should minor changes be necessary after submission, the submitting author should notify the IDDST Congress Secretariat by email, describing exactly the nature of the change to be made. The IDDST Congress organizers will then implement the change. In case of major changes, the authors should submit a revised abstract as an entirely new abstract and request the IDDST Congress Secretariat to delete the original abstract. The addition of a co-author constitutes a major change.
6. After completion of the abstract review, the submitting author will receive scheduling information via email. Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The presenting author must be registered as a IDDST Congress participant for final scheduling and publication of the abstract.
7. Accepted abstracts will be published in the IDDST Congress Proceedings, and in a (supplement to a) medical journal. Abstracts will not be released publicly before August 20, 2009. Click here for the abstract sample
|
|
About IDDST
